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Epstein-Barr virus (EBV)-infected, gastric epithelial cell line GT38 is resistant to TGF-1-mediated growth inhibition and
apoptosis, although TGF-1 partially induces EBV reactivation in the cells. These findings indicate that abnormalities exist in
these cells in the TGF-1-mediated signaling pathway, influencing growth inhibition and apoptosis. In order to characterize
the steps with abnormalities, we analyzed the TGF-1/MAPK/p21 pathway in the cells. TGF-1 activated MAPK (ERK 1/2) and
p21 in the TGF-1-susceptible cell line HSC-39 but not in GT38 cells. GT38 cells had higher constitutive levels of ERK 1/2
phosphorylation and p21 expression than did HSC-39 cells. U0126, a specific inhibitor of MEK, suppressed TGF-1-mediated
ERK 1/2 phosphorylation and p21 induction in HSC-39 cells and constitutive ERK 1/2 phosphorylation in GT38 cells. EBV
latent membrane protein 1 (LMP1) induced constitutive ERK 1/2 phosphorylation and NF-B activation in LMP1-transfected
HSC-39 cells, which then became resistant to TGF-1-mediated growth inhibition, TGF-1-mediated ERK 1/2 phosphoryla-
tion, and p21 induction, and proliferated in low-serum medium. These results are consistent with the conclusion that theINTRODUCTION
Epstein–Barr virus (EBV), which in humans causes
infectious mononucleosis, is also associated with vari-
ous epithelioid and lymphoid malignancies (Rickinson
and Kieff, 1996). Such a relationship exists between EBV
and gastric carcinoma (Shibata and Weiss, 1992;
Fukayama et al., 1994; Sugiura et al., 1996). The mono-
clonality of EBV DNA from infected gastric carcinoma
cells indicates that the tumors arise from a single EBV-
infected cell and that EBV infection occurs at a very early
stage in tumor development (Imai et al., 1994). Also,
elevated EBV antibody titers to viral lytic antigens, in sera
of patients with EBV-associated gastric adencarcinoma,
presumably reflects EBV reactivation in gastric carci-
noma cells (Imai et al., 1994; Levine et al., 1995). We have
shown that the EBV-infected epithelial cell lines GT38
and GT39, established from noncancerous segments of
gastric carcinoma resections, are resistant to TGF-1-
mediated growth inhibition and apoptosis, but are sen-
sitive to EBV reactivation (Fukuda et al., 2001).
TGF-1 is a multifunctional cytokine which negatively
regulates growth of most epithelial and endothelial cell
types (Massague, 2000). Loss of TGF- responsiveness
1 To whom correspondence and reprint requests should be ad-© 2002 Elsevier Science (USA)
All rights reserved.
310is likely to deregulate cellular growth in vivo, as an
important permissive step in tumor development. One
key event leading to TGF--induced growth arrest is
induction of expression of cyclin-dependent kinase
(CDK) inhibitors p15INK4B (Hannon and Brach, 1994),
p21WAF1/CIP1 (p21) (Datto et al., 1995), and p27kip1 (p27) (Yue
et al., 1998), depending on the cell type. p21 interacts
with complexes of CDK2 and cyclin A or cyclin E, inhib-
iting CDK2 activity, and thus preventing progression of
the cell cycle (Massague et al., 2000; Reynisdottir et al.,
1995). Activation of the Ras/MAPK pathway by TGF-
directly regulates expressions of p21 and p27 (Hu et al.,
1999; Yue et al., 1998).
The role of the Ras/MAPK cascade in TGF- signaling
is related to the transformation state of the cells. Since
many transformed cells have lost growth-inhibitory re-
sponsiveness to TGF-, normal signaling pathways acti-
vated by TGF- are expected to be altered (Hartsough et
al., 1998). Overactivity of Ras signaling cascades often
leads to cellular transformation, as well as resistance to
growth-inhibitory effects of TGF- (Longstreet et al.,
1992; Oft et al., 1996; Coppa et al., 1997).
Latant membrane protein 1 (LMP1) is considered to be
the principal oncoprotein of EBV, and is essential for
lymphocyte immortalization (Kaye et al., 1993). The ef-
fects of LMP1 on cellular growth and oncogenesis de-TGF-1/MAPK/p21 pathway is required for TGF-1-mediat
is derived from constitutive MAPK phosphorylation induce
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pend on its interactions with cellular proteins and intra-
cellular signaling pathways. Several domains of theed grow
d by LM
LMP1 cytoplasmic tail interact with TNF receptor-asso-
ciated factors (Mosialos et al., 1995) and TNF receptor-
associated death domain protein (Izumi and Kieff, 1997),
leading to activation of transcription factors NF-B (Huen
et al., 1995; Mitchell and Sugden, 1995) and AP-1 (Kieser
et al., 1997). LMP1 also activates the Ras/Raf-1/MEK/
MAPK pathway. Such MAPK (ERK 1/2) activation is re-
quired for malignant transformation of Rat-1 fibroblasts
(Roberts and Cooper, 1998). These observations lead us
to ask whether LMP1 mediates ERK 1/2 phosphorylation,
thereby inducing resistance to the growth-inhibitory ef-
fects of TGF-1.
In the current study, we have demonstrated that GT38
cells have a defect in the TGF-/MAPK/p21 signaling
pathway, which is mostly altered by LMP1.
RESULTS
TGF-1 induces ERK 1/2 phosphorylation and p21
expression in HSC-39 cells but not in GT38 cells
Previously we showed that EBV-infected cell lines
GT38 and GT39 are resistant to TGF-1-mediated growth
inhibition and apoptosis in the TGF-1-susceptible cell
line HSC-39 (Fukuda et al., 2001). A rapid and direct
activation of Ras-MAPK signaling pathway is associated
with growth inhibition by TGF-1 in epithelial cells (Hart-
sough and Mulder, 1996, 1997). Growth inhibition by
TGF-1 appears to be mediated in part by induction of
p21 (Malliri et al., 1996). Here we have analyzed MAPK
(ERK1 and ERK2) phosphorylation in HSC-39 and GT38
cells treated with TGF-1 by immunoblotting with a phos-
phospecific ERK1 and ERK2 (ERK 1/2) MAPK antibody
(Ab). TGF-1 induced ERK 1/2 phosphorylation at 1 min,
and phosphorylation decreased at 5 min in HSC-39 cells
(Fig. 1A). In contrast, GT38 cells had constitutively high
levels of ERK 1/2 phosphorylation in TGF-1-untreated
cells, with little influence of TGF-1 on ERK 1/2 phos-
phorylation (Fig. 1B).
We next investigated whether ERK 1/2 phosphorylation
regulated by TGF-1 is associated with p21 induction by
immunoblotting and with a WWP-Luc luciferase reporter
gene construct that contains the complete p21 promoter
region (Reynisdottir et al., 1995). HSC-39 and GT38 cells
were preincubated with or without U0126, a MEK-specific
inhibitor for both active and inactive MEK1, 2 (Favata et al.,
1998). Since ERK 1/2 phosphorylation and p21 expression
are induced by fetal bovine serum (FBS) (Zeng and el Deiry,
1996; Olson et al., 1998), we tested the effect of FBS on ERK
1/2 phosphorylation and p21 expression in both cell lines.
TGF-1 induced ERK 1/2 phosphorylation and p21 expres-
sion in HSC-39 cells, inductions that were both inhibited by
U0126 (Fig. 2A). In contrast, in GT38 cells, TGF-1 did not
induce ERK 1/2 phosphorylation and p21 expression. In
HSC-39 cells, ERK 1/2 phosphorylation and p21 expression
were induced by FBS; however, in GT38 cells, FBS had no
effect on ERK 1/2 phosphorylation and p21 expression. p21
induction occurred in TGF-1-treated HSC-39 cells but not
in GT38 cells, as judged by activation of p21 promoter,
using a luciferase reporter assay (Fig. 2B). These results
indicate that TGF-1 induces ERK 1/2 phosphorylation,
which is required for p21 expression in HSC-39, but not in
GT38 cells.
LMP1 induces the ERK 1/2 phosphorylation in HSC-
39 cells
The latency in GT38 cells is type III, which express
EBNA1, EBNA2, and LMP1 (Takasaka et al., 1998; Mu-
rakami et al., 2000). We hypothesized that in GT38 cells
constitutive ERK 1/2 phosphorylation depends on LMP1
expression, and inhibits TGF-1-mediated induction of ERK
1/2 phosphorylation and p21 expression. In order to test
this idea, HSC-39 cells were transfected with a LMP1 ex-
pression vector, and stably transfected G418-resistant
clones were tested for LMP1 expression and ERK 1/2 phos-
phorylation. Parental HSC-39 cells and HSC-39 (neo) cells
transfected with a control plasmid had little ERK 1/2 phos-
phorylation (Fig. 3). HSC-39 cells transfected with a consti-
FIG. 1. TGF-1 induces ERK 1/2 phosphorylation in HSC-39 but not in
GT38 cells. HSC-39 (A) and GT38 (B) cells were treated with TGF-1 (10
ng/ml) for the indicated times. Equal amounts of protein from the
respective cells were separated electrophoretically and blotted onto
membranes. ERK 1/2 phosphorylation was detected with an anti-phos-
phoMAPK Ab. Upper and lower arrows indicate ERK1 and ERK2, re-
spectively. Phosphorylation of the ERK 1/2 in TGF-1-treated vs control
cells was evaluated with laser densitometry (lower panel).
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tutively active ras mutant (Ras 12V), which induces ERK 1/2
phosphorylation (Webb et al., 1998), were used as a positive
control for ERK 1/2 phosphorylation. Constitutive ERK 1/2
phosphorylation was detected in LMP1-positive clones
(Cl-1, Cl-2, and Cl-7) (Fig. 3).
LMP1 inhibits TGF-1-mediated ERK 1/2
phosphorylation and p21 induction
We analyzed TGF-1-mediated ERK 1/2 phosphoryla-
tion and p21 induction in the LMP1-expressing HSC-39
clone (Cl-1). TGF-1 induced ERK 1/2 phosphorylation at
1 min (Fig. 4A) and expression of p21 at 24 h (Fig. 5A) in
the neo-transfected HSC-39 clone. In contrast, the LMP1-
expressing HSC-39 clone (Cl-1) and the Ras 12V-ex-
pressing HSC-39 clone (Cl-2) were resistant to TGF-1-
mediated ERK 1/2 phosphorylation (Figs. 4B and 4C) and
p21 induction (Figs. 5A and 5B).
To understand TGF-1- and FBS-mediated ERK 1/2
phosphorylation and p21 induction in other EBV-infected
cells, we analyzed them in the LMP1-negative Daudi cell
line (Satoh et al., 2002). TGF-1 and FBS induced ERK 1/2
phosphorylation and p21 expression in Daudi cells (Fig.
5C). The patterns of TGF-1- and FBS-induced ERK 1/2
phosphorylation and p21 expression were similar to
those observed patterns in HSC-39 cells (Fig. 2). The
result indirectly supports the conclusion that LMP1 in
EBV-infected cells inhibits TGF-1-mediated ERK 1/2
phosphorylation and p21 induction.
LMP-1-expressing HSC-39 cells are resistant to TGF-
1-mediated growth inhibition
LMP1 blocks TGF-1-mediated growth inhibition in
Burkitt’s lymphoma cell lines, and rat and mouse fibro-
blasts (Arvanitakis et al., 1995; Takanashi et al., 1999).
The effect of TGF-1 was tested on cell growth of the
LMP1-expressing HSC-39 clone (Cl-1) by the 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide
(MTT) assay (Fig. 6). TGF-1 inhibited cell growth in the
neo-transfected HSC-39 clone. In contrast, the Ras 12V-
expressing HSC-39 clone (Cl-2) and the LMP1-express-
FIG. 3. ERK 1/2 phosphorylation is induced in LMP1 expressing HSC-39
clones. HSC-39 clones (Cl-1, Cl-2, and Cl-7) and HSC-39 neo were stably
transfected with the LMP1 expression plasmid, or with vector alone,
respectively. The cells were lysed and assessed for the expression of
LMP1 by Western blotting using a monoclonal Ab to LMP1. The cells were
also analyzed for phosphorylation of ERKs using an anti-phosphoMAPK
Ab. An EBV-positive lymphoblastoid cell line (OB) and HSC-39 cells trans-
fected with a constitutively active rasmutant (Ras 12V) which induces ERK
1/2 phosphorylation were used as the positive controls (lane) for LMP1
and ERK 1/2 phosphorylation, respectively.
FIG. 2. TGF-1 induces the expression of p21 in HSC-39 cells but not in
GT38 cells. (A) Effects of TGF-1 and U0126 were tested on serum-starved
or unstarved cells. Cells were cultured with serum-free media for 24 h and
the cells were pretreated with or without MEK inhibitor U0126 (50 M) for
1 h and then were cultured with or without 10% FBS and TGF-1 (10 ng/ml)
for 24 h. Equal amounts of protein from the respective cells was separated
electrophoretically, blotted onto membranes, and then reacted with anti-
p21 Ab. In assaying ERK 1/2 phosphorylation, cells were pretreated with
U0126 (50 M) for 1 h, and then treated with TGF-1 (10 ng/ml) for 1 min.
The autoradiographs for p21 band intensities were analyzed by laser
densitometry (lower panel). (B) Cells were transiently transfected with the
WWP-Luc construct, which contains the complete p21 promoter region, by
using Trans IT-LT1 reagent. The cells were then cultured for 12 h in the
absence or presence of TGF-1 (10 ng/ml), and luciferase activities in cell
lysates were measured by using the dual luciferase reporter assay sys-
tem. The luciferase activity of p21 promoter were measured as lumines-
cence of firefly luciferase. The data are presented after normalization of the
transfection efficiency by using the renilla luciferase reporter gene. Results
are the means and standard deviations for three experiments.
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ing HSC-39 clone (Cl-1) were resistant to TGF-1-
mediated growth inhibition.
LMP1 activates NF-B through MAPK pathway
LMP1 activates NF-B in B lymphocytes, fibroblasts,
and epithelial cells (Rowe et al., 1994; He et al., 2000).
NF-B activation is required for LMP1-mediated transfor-
mation and tumorigenesis (He et al., 2000). In order to
analyze NF-B activity, we transfected luciferase reporter
plasmid pNF-B-Luc into, respectively, HSC-39 cells,
GT38 cells, the HSC-39 (neo) clone, and Ras 12V-, and
LMP1-expressing HSC-39 clones (Fig. 7). NF-B tran-
scriptional activity was low in both parental and neo-
transfected HSC-39 cells. In contrast, luciferase activities
in GT38 cells, the Ras 12V-expressing HSC-39 clone
(Cl-2), and the LMP1-expressing HSC-39 clone (Cl-1)
were about 7-, 3.5-, and 3-fold higher, respectively, than
that in parental HSC-39 cells (Fig. 7A).
To further dissect the mechanism of LMP1-mediated
NF-B activation, we assessed the effects of U0126 and
the potent NF-B inhibitor pyrrolidine dithiocarbamate
(PDTC) on ERK 1/2 phosphorylation and NF-B transcrip-
tional activity in GT38 cells and the LMP1-expressing
HSC-39 clone (Cl-1). LMP1-mediated ERK 1/2 phosphor-
ylation is a Ras-dependent pathway (Roberts and Coo-
per, 1998). Ras activates NF-B through MAPK pathway
(Arsura et al., 2000). U0126 inhibited both phosphoryla-
tion of ERK 1/2 and NF-B transcriptional activity in both
GT38 cells and the LMP1-expressing HSC-39 clone
FIG. 5. LMP-1 inhibits TGF-1-mediated p21 induction. (A) Cells were
pretreated with or without U0126 (50 M) for 1 h and then were cultured
with TGF-1 (10 ng/ml) for 24 h. Equal amounts of protein from the
respective cells were separated electrophoretically, blotted onto mem-
branes, and then reacted with anti-p21 Ab. The autoradiographs for p21
band intensities were analyzed by laser densitometry (lower panel). (B)
The luciferase activities of p21 promoter were performed as described
in Fig. 2B. (C) TGF-1 induces phosphorylation of ERK 1/2 and p21
expression in Daudi cells. Cells were cultured with serum-free media
for 24 h and the cells were pretreated with or without U0126 (50 M) for
1 h and then were cultured with or without 10% FBS and TGF-1 (10
ng/ml). For ERK 1/2 phosphorylation and p21 expression, cells were
treated with TGF-1 (10 ng/ml) for 5 min and 24 h, respectively. Equal
amounts of protein from the respective cells were separated electro-
phoretically, blotted onto membranes, and then reacted with anti-p21
Ab and an anti-phosphoMAPK Ab. The autoradiographs for p21 band
intensities were analyzed by laser densitometry (lower panel).
FIG. 4. TGF-1-mediated ERK 1/2 phosphorylation is inhibited in the
LMP1-transfected HSC-39 clone. HSC-39 cells were stably transfected
with (A) vector alone (neo), (B) Ras 12V, and (C) LMP1 and were
cultured with TGF-1 (10 ng/ml) for the indicated times. Equal amounts
of protein from the respective cells were separated electrophoretically
and blotted onto membranes. Phosphorylation of ERKs was analyzed
by Western blotting with an anti-phosphoMAPK Ab. Upper and lower
arrows indicate ERK1 and ERK2, respectively. Phosphorylation of the
ERKs in TGF-1-treated vs untreated control cells was evaluated with
laser densitometry (lower panel).
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(Cl-1) (Figs. 7B and 7C). In contrast, PDTC did not inhibit
ERK 1/2 phosphorylation but did inhibit NF-B transcrip-
tional activity in both GT38 cells and the LMP1-express-
ing HSC-39 clone (Cl-1). These results indicate that ac-
tivation of NF-B in GT38 cells is mediated by the LMP1/
MAPK pathway.
U0126 and PDTC inhibit cell growth of GT38 cells and
the LMP1-expressing HSC-39 clone, but the inhibition
patterns differ
The Ras-Raf-ERK/MAPK cascade is one major signal-
ing pathway regulating cell proliferation in many cell
types (Lenormand et al., 1993; Pages et al., 1993). NF-B
activity is a key mechanism of normal and malignant cell
growth control (Gilmore et al., 1996). We investigated the
effect of ERK 1/2 phosphorylation and NF-B activation
on cell growth of HSC-39 cells, GT38 cells, and neo-, Ras
12V-, and LMP1-transfected HSC-39 cells using the spe-
cific inhibitors U0126 and PDTC (Fig. 8). U0126 inhibited
cell growth in a dose-dependent manner (Fig. 8A).
Growth inhibition of Ras 12V- or LMP1-transfected
HSC-39 cells was greater than that of HSC-39 cells and
neo-transfected HSC-39 cells at the low concentration of
U0126 (10 M). The growth inhibition of PDTC was
greater than that of U0126, but the difference was not
significant (Fig. 8B). The growth inhibition rate was high-
est in GT38 cells, in the middle in Ras 12V- and LMP1-
transfected clones, and lowest in HSC-39 cells and the
neo-transfected HSC-39 clone. These results indicate
that ERK 1/2 phosphorylation and NF-B activity are
essential for cell proliferation and that the inhibition pat-
terns are reflected by the signal intensity of ERK 1/2
phosphorylation and NF-B activation in the cells.
FIG. 7. LMP1 induces NF-B activation in HSC-39 cells. (A) Cells
were transiently transfected with the pNF-B-Luc construct by using
Trans IT-LT1 reagent. After 48 h incubation, luciferase activity in cell
lysate was measured by using the dual luciferase reporter assay
system. The luciferase activities of NF-B promoter were measured as
luminescence of firefly luciferase. The data are presented after normal-
ization of the transfection efficiency by using the renilla luciferase
reporter gene. Results are the means and standard deviations for three
experiments. (B) U0126 but not PDTC inhibits ERK 1/2 phosphorylation
in GT38 cells and LMP1-expressing HSC-39 clone. Cells were treated
with or without various concentrations of U0126 or PDTC for 1 h. Equal
amounts of protein from the respective cells were separated electro-
phoretically and blotted onto membranes. Phosphorylation of ERKs
was analyzed by Western blotting with an anti-phosphoMAPK Ab.
Upper and lower arrows indicate ERK1 and ERK2, respectively. (C)
U0126 and PDTC inhibit NF-B activation in GT-38 cells and the LMP1-
expressing HSC-39 clone (Cl-1). Cells were treated with or without
U0126 (50 M) or PDTC (100 M) for 1 h. Cells were transiently
transfected with the pNF-B-Luc construct by using Trans IT-LT1 re-
agent. After 48 h incubation, luciferase activity in cell lysate was measured
by using the dual luciferase reporter assay system. The luciferase activi-
ties of NF-B promoter were performed as described in (A).
FIG. 6. LMP-1- and Ras 12V-transfected HSC-39 clones are resistant
to TGF-1-mediated growth inhibition. HSC-39 clones stably trans-
fected with vector alone (neo); Ras 12V or LMP1 were seeded at 5 
103 cells/100 l per well and then were cultured with 0.5 or 1 ng/ml
TGF-1 for 72 h. Cell growth was measured by MTT assay. Results are
the means and standard deviations for five experiments.
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LMP1 promotes growth of HSC-39 cells in low-serum
medium
To test whether ERK 1/2 phosphorylation by FBS is
crucial to cell growth in HSC-39 cells, GT38 cells, the
HSC-39 (neo) clone, and Ras 12V-, and LMP1-expressing
HSC-39 clones, we tested growth of these cells in me-
dium containing 3, 1, and 0.1% FBS using the MTT assay
(Fig. 9). All cells proliferated in 3% FBS-containing me-
dium. In 0.1% FBS-containing medium, the GT38 cells, the
FIG. 8. Effect of U0126 and PDTC on the cell growth of HSC-39 cells, GT38 cells, HSC-39 neo, and Ras 12V- and LMP1-expressing HSC-39 clones.
The cells (5  103 cells/100 l) were cultured for 72 h with various concentrations of U0126 (A) and PDTC (B). Cell growth was measured by MTT
assay. Results are the means and standard deviations for five experiments.
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Ras 12V-expressing HSC-39 clone (Cl-2), and the LMP1-
expressing HSC-39 clone (Cl-1) proliferated, while the
HSC-39 cells and the HSC-39 (neo) clone did not.
DISCUSSION
We investigated the mechanism for resistance to TGF-
1-mediated growth inhibition in the EBV-infected epi-
thelial cell line GT38. In the cells, TGF-1 induced little
PAI-1 expression, while junB was rapidly and strongly
induced (Fukuda et al., 2001). Ras/MAPK activation is
obligatory for TGF-1-mediated PAI-1 expression in car-
diac myocytes (Abdellatif et al., 1994). However, the MEK
inhibitor U0126 inhibits TGF-1-mediated EBV reactiva-
tion in EBV-infected BL cells (Fahmi et al., 2000), but does
not suppress TGF-1-mediated EBV reactivation in GT38
cells (data not shown). These results lead us to postulate
that GT38 cells have an abnormality in the TGF-/MAPK
signaling pathway. A paradigm is emerging whereby
multiple signals use the Ras/MAPK signaling cascade to
induce p21 and cause growth arrest. In this study, we
focused on the TGF-/MAPK/p21 signaling pathway in
GT38 cells.
First, we demonstrated that GT38 cells had constitu-
tively high levels of ERK 1/2 phosphorylation and were
resistant to TGF-1-mediated ERK 1/2 phosphorylation
and p21 induction (Figs. 1 and 2). In contrast, HSC-39
cells had constitutively low levels of ERK 1/2 phosphor-
ylation and p21 expression, both of which were markedly
enhanced by TGF-1. Using U0126, we confirmed that
constitutive ERK 1/2 phosphorylation in GT38 cells and
TGF-1-mediated ERK 1/2 phosphorylation in HSC-39
cells were required for p21 expression in these cells.
Second, we showed that LMP1 induced constitutive
ERK 1/2 phosphorylation in HSC-39 cells, and that the
LMP1-expressing HSC-39 clones were resistant to TGF-
1-mediated growth inhibition (Figs. 3 and 6). It has been
reported that lack of responsiveness to TGF-1 corre-
lates with down-regulation of TGF- type II receptor
expression in BL cell lines (Kumar et al., 1991; Inman and
Allday, 2000). We confirmed that TGF- type I and II
receptors were expressed in the LMP1-expressing
HSC-39 clones (data not shown). These results suggest
that the resistance of TGF-1-mediated growth inhibition
in the LMP1-expressing clones was not due to the re-
duction of TGF- type I and II receptors.
Third, we found that TGF-1-mediated ERK 1/2 phos-
phorylation and p21 induction were inhibited in the
LMP1-expressing HSC-39 clones (Figs. 4 and 5). We
used the Ras 12V-expressing HSC-39 clone as the pos-
itive control for ERK 1/2 phosphorylation. The Ras 12V-
FIG. 9. Growth kinetics of HSC-39 cells, GT38 cells, HSC-39 neo, and Ras 12V- and LMP1-expressing HSC-39 clones at low FBS concentrations.
The cells (1  104 cells/100 l) were cultured with medium containing 3, 1, and 0.1% FBS for 2, 4, and 6 days, respectively. Cell growth was measured
by MTT assay. Results are the means and standard deviations for five experiments.
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expressing HSC-39 clone also had constitutive ERK 1/2
phosphorylation in which TGF-1-mediated ERK 1/2
phosphorylation and p21 induction were inhibited. These
results indicate that constitutive ERK 1/2 phosphorylation
inhibits TGF-1-mediated ERK 1/2 phosphorylation and
p21 induction. TGF-1 did not induce ERK 1/2 phosphor-
ylation and p21 expression in GT38 cells, but partially
induced p21 expression in LMP1- or Ras 12V-transfected
HSC-39 cells. Constitutive ERK 1/2 phosphorylation was
not seen in EBV-positive, but LMP1-negative Daudi cells
and TGF-1 induced ERK 1/2 phosphorylation and p21
induction in the cells (Fig. 5C). Taken together, these
results indicate that LMP1- or Ras 12V-mediated ERK 1/2
phosphorylation is necessary for the inhibition of TGF-
1-mediated p21 induction and complete inhibition in
GT38 cells may be mediated by other factors.
Fourth, we demonstrated that LMP1 induces not only
ERK 1/2 phosphorylation but also NF-B activation in
LMP1-expressing HSC-39 clones (Figs. 3, 4, and 7). We
demonstrated that LMP1 activates NF-B through the
MAPK pathway using the specific inhibitors U0126 and
PDTC (Fig. 7). ERK 1/2 phosphorylation and NF-B acti-
vation are needed for cell growth in many cell types
(Pages et al., 1993; Gilmore et al., 1996). We showed that
ERK 1/2 phosphorylation and NF-B activation are cru-
cial for cell growth of HSC-39 cells, GT38 cells, and neo-
or LMP1-transfected HSC-39 cells using U0126 and
PDTC (Fig. 8). U0126 and PDTC inhibited cell growth in a
dose-dependent fashion. More than 10 M U0126 almost
completely inhibited ERK 1/2 phosphorylation in both
GT38 cells and the LMP1-expressing HSC-39 clone;
however, 10 M U0126 did not completely inhibit cell
growth in them (Fig. 8A). Furthermore, 100 M PDTC did
not completely inhibit NF-B transcriptional activity in
GT38 cells and the LMP1-expressing HSC-39 clone.
More than 5 M PDTC almost completely inhibited cell
growth in every case (Figs. 8B). The growth inhibition of
PDTC was greater than that of U0126. These results
indicate that NF-B activity is associated more directly
with cell growth than ERK 1/2 phosphorylation. However,
the specifity and mechanism of these inhibitors must be
evaluated carefully, because these compounds inhibit
many targets, sometimes much more potently than their
presumed targets (Davies et al., 2000). On the other
hand, serum stimulation induces MAPK (ERK) phosphor-
ylation via the Raf/MEK signal transduction cascade
(Seger and Krebs, 1995; Greulich and Erikson, 1998).
Parental and neo-transfected HSC-39 cells did not pro-
liferate in 0.1% FBS-containing medium. In contrast, GT38
cells, or Ras 12V- or LMP1-expressing HSC-39 clones
could proliferate in 0.1% FBS-containing medium (Fig. 9).
These results indicate that ERK 1/2 phosphorylation by
FBS is critical for cell growth of parental and neo-trans-
fected HSC-39 cells. The constitutive ERK 1/2 phosphor-
ylation by LMP1 or Ras 12V might enable cell growth at
low serum concentrations in GT38 cells, or Ras 12V- or
LMP1-expressing HSC-39 clones. However, Ras 12V- or
LMP1-expressing HSC-39 clones could not proliferate
well in low-serum medium compared to GT38 cells. This
indicates that other pathways could be involved in GT38
cells.
Smad proteins play a pivotal role in the TGF- signal-
ing pathway, and here we show that the MAPK pathway
is also essential for p21 induction by TGF-1. It has been
suggested that Ras 12V abrogates TGF- signaling
by MAP kinase-dependent phosphorylation of Smad2/
Smad3 and their nuclear translocation (Kretzschmar et
al., 1999). There is cross-talk between the p42/p44 MAPK
and Smad pathways in TGF-1-induced furin gene trans-
activation (Blanchette et al., 2001). It remains to be de-
termined whether cross-talk also exists between the
TGF-1/MAPK and TGF-1/Smad pathways in various
TGF-1-mediated gene expressions in GT38 cells.
In summary, we demonstrate that GT38 cells have a
constitutive ERK 1/2 phosphorylation and a nonrespon-
siveness of TGF--mediated ERK 1/2 phosphorylation
and p21 induction. LMP1 induces not only constitutive
ERK 1/2 phosphorylation but also NF-B activation and
inhibits TGF-1-mediated ERK 1/2 phosphorylation and
p21 induction in HSC-39 cells. These results are consis-
tent with the conclusions that constitutive ERK 1/2 phos-
phorylation by LMP1 makes GT38 cells nonresponsive in
the TGF-/MAPK/p21 pathway and that ERK 1/2 phos-
phorylation and NF-B activation by LMP1 are critical
events in resistance to TGF-1-mediated growth inhibi-
tion and growth promotion of EBV-infected cells.
MATERIALS AND METHODS
Cell lines and medium
GT38 cells were an EBV-positive epithelial cell line
from human gastric tissues (Tajima et al., 1998). The
HSC-39 cell line was derived from a human signet ring
cell gastric carcinoma (Yanagihara et al., 1991). Daudi
cells were an EBV-positive Burkitt’s lymphoma cell line
(Nadkarni et al., 1969). Cells were grown in RPMI 1640
medium supplemented with 10% heat-inactivated FBS,
100 U/ml penicillin, 100 g/ml streptomycin at 37°C in a
humidified atmosphere of 5% CO2 in air.
Antibodies and other reagents
TGF-1 was purchased from Pepro Tech EC Ltd. (Lon-
don, England). Anti-human p21 monoclonal Ab was pur-
chased from Pharmingen (San Diego, CA). Anti-TGF- R
I (V-22) and anti-TGF- R II (H-567) Abs were purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Anti-phosphoMAPK (ERK1 and ERK2) Ab was purchased
from Promega (Madison, WI). Anti-rabbit and anti-mouse
Abs conjugated to alkaline phosphatase were pur-
chased from Boehringer Mannheim (Mannheim, Ger-
many) and New England Biolabs (Boverly, MA), respec-
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tively. U0126 and PDTC were purchased from Calbio-
chem (Cosmobio, Tokyo, Japan) and Sigma (Sigma–
Aldrich, Tokyo, Japan), respectively, and dissolved in
dimethyl sulfoxide before addition to culture medium.
Luciferase constructs WWP-Luc (el Deiry et al., 1993) and
pNF-B-Luc (Stratagene) were provided by Drs. B. Vo-
gelstein and K. Hirota, respectively.
Colorimetric assay for cell proliferation
Cell growth was assayed by incorporation of MTT dye
(Chemicon Int., Inc., Temecula, CA). Cells were seeded in
96-well plates (Corning, Inc., Corning, NY) at 5  103
cells/100 l per well and cultured with various concen-
trations of TGF-1 for 72 h. Ten microliters of MTT solu-
tion (5 mg/ml) was added to each well, and the plates
were incubated for 4 h at 37°C. One hundred microliters
isopropanol with 0.04 N HCl was added to each well and
mixed by repeated pipetting. Absorbance was measured
at a test wavelength of 570 nm and a reference wave
length of 655 nm with a microplate reader (Model 550,
Bio-Rad, Richmond, CA).
Western blotting
Cells were washed with ice-cold phosphate-buffered
saline (PBS), containing 1 mM sodium vanadate for de-
tection of the phosphorylation of MAPK, treated with 10%
trichloroacetic acid on ice for 15 min, collected in a
microcentrifuge tube, and centrifuged at 15,000 rpm, 0°C
for 5 min. The pellets were lysed in 100 l of lithium
dodecylsulfate (LDS) sample buffer containing 125 mM
Tris–HCl (pH 6.8), 2.3% (w/v) LDS, 10% (w/v) glycerol, 5%
(v/v) 2-mercaptoethanol, and 10 g/ml bromphenol blue
and boiled for 5 min. Proteins were resolved by 10 or 15%
SDS–PAGE and transferred to a PVDF membrane (Milli-
pore, Bedford, MA). Blotting of equal amounts of protein
to the membrane was confirmed by Coomassie Brilliant
Blue R-250 dye staining. After blocking incubation with
PBS–Tween 20 containing 5% nonfat dry milk powder for
2 h at RT, the membranes were incubated with primary
Abs overnight at 4°C. Following primary Abs incubation,
the membranes were incubated with secondary Abs. The
membranes were further processed using the Western-
light chemiluminescent detection system (Tropix, Bed-
ford, MA).
Stable transfection
To construct inducible vectors, an EcoRI–KpnI frag-
ment encoding human-H-Ras 12V protein (gift from Dr. H.
Kitayama) was inserted into the EcoRI–KpnI site of the
pcDNA3 vector. Transfection of pRcCMV-LMP1 (gift from
Dr. M. Takanashi; Takanashi et al., 1999), pcDNA3-LMP1
(gift from Dr. H. Sato; Takeshita et al., 1998), and pcDNA3-
Ras V12 was carried out by the electroporation method.
Cells (5  106) were suspended in 300 l of ice-cold
K-phosphate buffer saline containing 30 g of LMP1, Ras
V12-expression plasmids, or the control plasmids. Cells
were then electroporated with a Gene pulser II (Bio-Rad,
Richmond, CA) at room temperature in cuvettes with a
0.4-cm electrode gap. Transfected HSC-39 cells were
cultured in 3 ml of culture medium for 2 days and then
transferred to 96-well, flat-bottom plates at 1  104 cells
per well in complete culture medium containing 700 g
of G418 (Life Tech, GIBCO BRL, Tokyo, Japan) per milli-
liter. Seven single clones were isolated after 3–4 weeks.
After clonal expansion, cells from each individual clone
were screened for expressions of LMP1 by immunoblot-
ting or Ras 12V (data not shown) by Northern blotting.
Parental HSC-39 cells were also transfected with control
expression vectors containing the neomycin-resistant
gene (pRcCMV or pcDNA3), and the resulting clones
were pooled and termed “neo-transfected.”
Transcriptional response assay
Cells were transiently transfected with WWP-Luc or
pNF-B-Luc promoter–reporter constructs by using
Trans IT-LT1 reagent (Takara, Kyoto, Japan). Cells were
plated overnight at 5  105 cells/well in 12-well plates.
The mixture of plasmids and LT1 reagent was added,
and the cells were incubated for 30 h at 37°C. The cells
were treated with or without 10 ng/ml TGF-1, followed
by incubation at 37°C for 12 h to detect WWP-Luc lucif-
erase activity. For normalization of the transfection effi-
ciency, the Renilla luciferase reporter gene in pRL-TK
vector (Promega, Tokyo, Japan) was cotransfected in
each transfection. Luciferase activity in cell lysates was
measured with a luminometer using the dual luciferase
reporter assay system (Promega) according to the man-
ufacturer’s protocol. The luciferase activities of p21 pro-
moter in WWP-Luc construct and NF-B promoter in
pNF-B-Luc construct were measured according to the
luminescence of firefly luciferase. For an internal control,
renilla luciferase was measured immediately afterward
by quenching the firefly luminescence.
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